Kurs
+3,75%
Likviditet
0,45 MSEK
Kalender
Est. tid* | ||
2026-08-31 | 12:30 | Bokslutskommuniké 2026 |
2026-05-05 | 11:20 | Kvartalsrapport 2026-Q3 |
2026-02-25 | 11:20 | Kvartalsrapport 2026-Q2 |
2025-11-04 | N/A | Årsstämma |
2025-11-03 | 11:20 | Kvartalsrapport 2026-Q1 |
2025-08-29 | 12:30 | Bokslutskommuniké 2025 |
2025-04-29 | - | Kvartalsrapport 2025-Q3 |
2025-02-27 | - | Kvartalsrapport 2025-Q2 |
2024-11-01 | - | X-dag ordinarie utdelning DEX 0.00 SEK |
2024-10-31 | - | Årsstämma |
2024-10-24 | - | Kvartalsrapport 2025-Q1 |
2024-08-30 | - | Bokslutskommuniké 2024 |
2024-04-26 | - | Kvartalsrapport 2024-Q3 |
2024-02-15 | - | Kvartalsrapport 2024-Q2 |
2023-11-01 | - | X-dag ordinarie utdelning DEX 0.00 SEK |
2023-10-31 | - | Årsstämma |
2023-10-27 | - | Kvartalsrapport 2024-Q1 |
2023-08-30 | - | Bokslutskommuniké 2023 |
2023-04-28 | - | Kvartalsrapport 2023-Q3 |
2023-02-15 | - | Kvartalsrapport 2023-Q2 |
2022-10-31 | - | X-dag ordinarie utdelning DEX 0.00 SEK |
2022-10-28 | - | Årsstämma |
2022-10-27 | - | Kvartalsrapport 2023-Q1 |
2022-08-30 | - | Bokslutskommuniké 2022 |
2022-05-11 | - | Extra Bolagsstämma 2022 |
2022-04-29 | - | Kvartalsrapport 2022-Q2 |
2022-02-15 | - | Kvartalsrapport 2022-Q1 |
2021-11-26 | - | X-dag ordinarie utdelning DEX 0.00 SEK |
2021-11-25 | - | Årsstämma |
2021-08-29 | - | Bokslutskommuniké 2021 |
2021-04-29 | - | Kvartalsrapport 2021-Q3 |
2021-02-02 | - | Kvartalsrapport 2021-Q2 |
2020-10-22 | - | Kvartalsrapport 2021-Q1 |
2020-10-09 | - | X-dag ordinarie utdelning DEX 0.00 SEK |
2020-10-08 | - | Årsstämma |
2020-08-28 | - | Bokslutskommuniké 2020 |
2020-05-06 | - | Kvartalsrapport 2020-Q3 |
2020-01-31 | - | Kvartalsrapport 2020-Q2 |
2019-10-24 | - | Kvartalsrapport 2020-Q1 |
2019-10-17 | - | Årsstämma |
2019-10-11 | - | X-dag ordinarie utdelning DEX 0.00 SEK |
2019-08-30 | - | Bokslutskommuniké 2019 |
2019-05-28 | - | Extra Bolagsstämma 2019 |
2019-04-24 | - | Kvartalsrapport 2019-Q3 |
2018-10-18 | - | Kvartalsrapport 2019-Q1 |
2018-10-11 | - | X-dag ordinarie utdelning DEX 0.00 SEK |
2018-10-10 | - | Årsstämma |
2018-08-31 | - | Bokslutskommuniké 2018 |
2018-04-25 | - | Kvartalsrapport 2018-Q3 |
2018-01-29 | - | Kvartalsrapport 2018-Q2 |
2017-11-10 | - | X-dag ordinarie utdelning DEX 0.00 SEK |
2017-11-09 | - | Årsstämma |
2017-10-18 | - | Kvartalsrapport 2018-Q1 |
2017-08-31 | - | Bokslutskommuniké 2017 |
2017-04-27 | - | Kvartalsrapport 2017-Q3 |
2017-02-28 | - | Kvartalsrapport 2017-Q2 |
2016-11-30 | - | Årsstämma |
2016-11-30 | - | Kvartalsrapport 2017-Q1 |
2016-11-04 | - | X-dag ordinarie utdelning DEX 0.00 SEK |
2016-09-13 | - | Extra Bolagsstämma 2016 |
2016-08-31 | - | Bokslutskommuniké 2016 |
2016-05-26 | - | Kvartalsrapport 2016-Q3 |
2016-02-25 | - | Kvartalsrapport 2016-Q2 |
2015-11-27 | - | Kvartalsrapport 2015-Q1 |
2015-11-26 | - | Kvartalsrapport 2016-Q1 |
2015-11-04 | - | X-dag ordinarie utdelning DEX 0.00 SEK |
2015-11-03 | - | Årsstämma |
2015-08-27 | - | Bokslutskommuniké 2015 |
2015-05-28 | - | Kvartalsrapport 2015-Q3 |
2015-02-26 | - | Kvartalsrapport 2015-Q2 |
2014-11-28 | - | X-dag ordinarie utdelning DEX 0.00 SEK |
2014-11-27 | - | Årsstämma |
2014-08-29 | - | Bokslutskommuniké 2014 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Bioteknik |
OsteoDex, the company's phase 2b study for the treatment of advanced prostate cancer, so-called castration-resistant metastatic prostate cancer (mCRPC), will have complete follow-up for all patients at the end of April 2020, which concludes the phase II study. The results will be reported in May 2020. Interim results at today's date are still very promising with significantly longer survival for patients who responded to treatment compared to the other patients. A handful of big pharma companies interested in OsteoDex have announced that they want to wait for the final results for patients' survival, which will be reported to them in May 2020.
DexTech's goal is to sign a license agreement regarding OsteoDex before the end of 2020.
The treatment of mCRPC has as a fundamental goal to be life-prolonging and preferably with acceptable side effects.
"- We have full understanding that our interested parties want to see the final result of the follow up. I think we have very good possibilities to achieve the ultimate goal with the OsteoDex treatment," says CEO Anders R Holmberg.
For additional information:
Gösta Lundgren - CFO & Investor Relations
DexTech Medical AB
Telephone: +46 (0) 707104788
E-mail: gosta.lundgren@dextechmedical.com
This information is information that Dextech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on February 18, 2020.